These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 21220747)

  • 61. Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy.
    Gibbons DL; Pricl S; Posocco P; Laurini E; Fermeglia M; Sun H; Talpaz M; Donato N; Quintás-Cardama A
    Proc Natl Acad Sci U S A; 2014 Mar; 111(9):3550-5. PubMed ID: 24550512
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Targeting integrated stress response with ISRIB combined with imatinib treatment attenuates RAS/RAF/MAPK and STAT5 signaling and eradicates chronic myeloid leukemia cells.
    Dudka W; Hoser G; Mondal SS; Turos-Korgul L; Swatler J; Kusio-Kobialka M; Wołczyk M; Klejman A; Brewinska-Olchowik M; Kominek A; Wiech M; Machnicki MM; Seferynska I; Stoklosa T; Piwocka K
    BMC Cancer; 2022 Dec; 22(1):1254. PubMed ID: 36460969
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph
    Willmann M; Sadovnik I; Eisenwort G; Entner M; Bernthaler T; Stefanzl G; Hadzijusufovic E; Berger D; Herrmann H; Hoermann G; Valent P; Rülicke T
    Exp Hematol; 2018 Jan; 57():50-59.e6. PubMed ID: 29031704
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones.
    Quintás-Cardama A; Cortes J
    Leuk Res; 2008 Aug; 32(8):1313-6. PubMed ID: 18242697
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Evolution of chronic myeloid leukemia on nilotinib after failure of imatinib].
    Sawadogo S; Hien FM; Ouédraogo MS; Drabo YJ
    Pan Afr Med J; 2014; 18():142. PubMed ID: 25419280
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies.
    Quintás-Cardama A; Tong W; Manshouri T; Vega F; Lennon PA; Cools J; Gilliland DG; Lee F; Cortes J; Kantarjian H; Garcia-Manero G
    Leukemia; 2008 Jun; 22(6):1117-24. PubMed ID: 18401417
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice.
    Nieborowska-Skorska M; Hoser G; Hochhaus A; Stoklosa T; Skorski T
    Leukemia; 2013 Nov; 27(11):2253-4. PubMed ID: 23604228
    [No Abstract]   [Full Text] [Related]  

  • 68. Real-time fluorescent resonance energy transfer analysis to monitor drug resistance in chronic myelogenous leukemia.
    Tunceroglu A; Matsuda M; Birge RB
    Mol Cancer Ther; 2010 Nov; 9(11):3065-73. PubMed ID: 20817824
    [TBL] [Abstract][Full Text] [Related]  

  • 69. JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.
    Gallipoli P; Cook A; Rhodes S; Hopcroft L; Wheadon H; Whetton AD; Jørgensen HG; Bhatia R; Holyoake TL
    Blood; 2014 Aug; 124(9):1492-501. PubMed ID: 24957147
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Novel pharmacological approach for the prevention of multidrug resistance (MDR) in a human leukemia cell line.
    Gupta SK; Singh P; Chhabra R; Verma M
    Leuk Res; 2021 Oct; 109():106641. PubMed ID: 34144313
    [TBL] [Abstract][Full Text] [Related]  

  • 71. STAT5 inhibitor Pimozide as a probable therapeutic option in overcoming Ponatinib resistance in K562 leukemic cells.
    Gumus N; Gunduz C; Tezcanli Kaymaz B
    J Biomol Struct Dyn; 2023 Jan; 41(1):186-199. PubMed ID: 34842047
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia.
    Schafranek L; Nievergall E; Powell JA; Hiwase DK; Leclercq T; Hughes TP; White DL
    Leukemia; 2015 Jan; 29(1):76-85. PubMed ID: 24813920
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Inhibition of Tumoral VISTA to Overcome TKI Resistance via Downregulation of the AKT/mTOR and JAK2/STAT5 Pathways in Chronic Myeloid Leukemia.
    Ai K; Chen M; Liang Z; Ding X; Gao Y; Zhang H; Wu S; He Y; Li Y
    Biomol Ther (Seoul); 2024 Sep; 32(5):582-600. PubMed ID: 39104205
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Biology: Three known unknowns.
    Bourzac K
    Nature; 2014 May; 509(7502):S69-71. PubMed ID: 24870828
    [No Abstract]   [Full Text] [Related]  

  • 75. BCR/ABL1ΔE7-8-9 isoform contributes to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
    Tan Y; Zhang L; Zhu G; Yang Y; Guo W; Chen L; Chang J; Xu Y; Muyey DM; Wang H
    Hematol Oncol; 2022 Dec; 40(5):1067-1075. PubMed ID: 35686657
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Inhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemia.
    Berger A; Sexl V; Valent P; Moriggl R
    Oncotarget; 2014 Oct; 5(20):9564-76. PubMed ID: 25333255
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia.
    Scherr M; Kirchhoff H; Battmer K; Wohlan K; Lee CW; Ricke-Hoch M; Erschow S; Law E; Kloos A; Heuser M; Ganser A; Hilfiker-Kleiner D; Heidenreich O; Eder M
    Leukemia; 2019 Jun; 33(6):1313-1323. PubMed ID: 30546081
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Molecular response to first line nilotinib in a patient with e19a2 BCR-ABL1 chronic myeloid leukemia.
    Langabeer SE; McCarron SL; Carroll P; Kelly J; O'Dwyer M; Conneally E
    Leuk Res; 2011 Sep; 35(9):e169-70. PubMed ID: 21641037
    [No Abstract]   [Full Text] [Related]  

  • 79. BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia.
    Amarante-Mendes GP; Rana A; Datoguia TS; Hamerschlak N; Brumatti G
    Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057108
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Precision Deuteration in Search of Anticancer Agents: Approaches to Cancer Drug Discovery.
    Mourya A; Prajapati N
    Cancer Biother Radiopharm; 2024 Feb; 39(1):1-18. PubMed ID: 37585602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.